Comprehensive information on GLP-1 medications written for patients, including efficacy data, contraindications, and potential side effects, may be accessed via this document from the Department of Texas Health and Services.
FDA prescriber information data sheets for semaglutide may be accessed here.
FDA prescriber information data sheets for tirzepatide may be accessed here.
Treatment effects for semaglutide were first described in this 2021 study in the New England Journal of Medicine. These findings were confirmed in the STEP 5 Trial published in Nature Medicine in 2022.
Treatment effects for tirzepatide were first described in this 2022 study, also published in the New England Journal of Medicine.
Multiple trials showing reduction in risk of adverse cardiac events such as heart attack in patients taking GLP-1 agonist medication may be reviewed here and here.
Further resources are available on request.
